RHYTHM PHARMACEUTICALS INC's ticker is RYTM and the CUSIP is 76243J105. A total of 111 filers reported holding RHYTHM PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.05 and the average weighting 0.1%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $24,432,204 | +37.4% | 1,065,745 | -1.2% | 0.02% | +45.5% |
| Q2 2023 | $17,779,404 | -9.2% | 1,078,207 | -1.8% | 0.01% | -15.4% |
| Q1 2023 | $19,581,047 | -45.8% | 1,097,573 | -11.5% | 0.01% | -50.0% |
| Q4 2022 | $36,113,017 | -5.7% | 1,240,153 | -60.3% | 0.03% | -10.3% |
| Q3 2022 | $38,285,247 | +343.5% | 3,122,166 | +50.1% | 0.03% | +383.3% |
| Q2 2022 | $8,632,000 | -74.6% | 2,080,077 | -29.5% | 0.01% | -62.5% |
| Q1 2022 | $33,995,000 | +8.7% | 2,951,002 | -5.8% | 0.02% | +23.1% |
| Q4 2021 | $31,277,000 | -24.7% | 3,133,935 | -1.5% | 0.01% | -27.8% |
| Q3 2021 | $41,562,000 | -45.9% | 3,182,382 | -18.9% | 0.02% | -45.5% |
| Q2 2021 | $76,872,000 | -11.6% | 3,926,050 | -4.0% | 0.03% | -17.5% |
| Q1 2021 | $86,951,000 | -34.9% | 4,088,023 | -9.0% | 0.04% | -35.5% |
| Q4 2020 | $133,542,000 | +40.5% | 4,491,765 | +2.4% | 0.06% | +24.0% |
| Q3 2020 | $95,053,000 | -3.4% | 4,386,370 | -0.5% | 0.05% | -9.1% |
| Q2 2020 | $98,353,000 | +49.6% | 4,410,488 | +2.1% | 0.06% | +22.2% |
| Q1 2020 | $65,735,000 | -33.5% | 4,319,033 | +0.3% | 0.04% | -11.8% |
| Q4 2019 | $98,848,000 | +34.4% | 4,305,248 | +26.4% | 0.05% | +27.5% |
| Q3 2019 | $73,552,000 | +1.5% | 3,406,748 | +3.5% | 0.04% | +2.6% |
| Q2 2019 | $72,431,000 | -19.5% | 3,292,325 | +0.3% | 0.04% | -22.0% |
| Q1 2019 | $89,953,000 | +2.6% | 3,281,769 | +0.6% | 0.05% | -10.7% |
| Q4 2018 | $87,714,000 | -1.4% | 3,263,175 | +7.0% | 0.06% | +16.7% |
| Q3 2018 | $88,993,000 | +24.2% | 3,050,838 | +33.1% | 0.05% | +17.1% |
| Q2 2018 | $71,641,000 | +228.9% | 2,291,785 | +109.4% | 0.04% | +215.4% |
| Q1 2018 | $21,783,000 | -0.7% | 1,094,620 | +45.0% | 0.01% | -7.1% |
| Q4 2017 | $21,945,000 | – | 755,160 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 2,075,000 | $47,569,375 | 5.56% |
| NEA Management Company, LLC | 2,909,956 | $66,710,741 | 5.15% |
| Opaleye Management Inc. | 653,000 | $14,970,025 | 4.87% |
| Frazier Life Sciences Management, L.P. | 2,371,304 | $54,362,144 | 3.61% |
| VR Adviser, LLC | 1,090,000 | $24,988,250 | 2.63% |
| RA Capital Management | 5,676,067 | $130,123,836 | 2.56% |
| Samsara BioCapital, LLC | 345,293 | $7,915,842 | 2.42% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 260,537 | $5,972,811 | 1.81% |
| Logos Global Management LP | 400,000 | $9,170,000 | 1.22% |
| Cormorant Asset Management, LP | 850,000 | $19,486,250 | 1.14% |